SCHEMBL26124702

SCHEMBL26124702

CCOC(=O)C(=CN(C)C)C(=O)C(C)OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.45
NPSR1 Q6W5P4 4/20 0.41
GLO1 Q04760 1/20 0.41
ALDH1A1 P00352 5/20 0.37
CYP2D6 P10635 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
MAPT P10636 6/20 0.34
LMNA P02545 4/20 0.34
PLIN1 O60240 1/20 0.34
POLB P06746 1/20 0.34
PLIN5 Q00G26 1/20 0.34
ABHD5 Q8WTS1 1/20 0.34
CYP2C19 P33261 2/20 0.33
CYP1A2 P05177 1/20 0.33
S1PR4 O95977 1/20 0.33
S1PR1 P21453 1/20 0.33
MAPK1 P28482 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546605 1.00 CYP2C9 (0.45) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL13556621 0.87 CYP2C9 (0.45) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL1587530 0.85 CYP2C9 (0.49) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL5901707 0.85 CYP2C9 (0.49) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL1587531 0.85 CYP2C9 (0.49) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL3589914 0.82 CYP2C9 (0.46) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL13672504 0.82 CYP2C9 (0.46) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL5599122 0.82 CYP2C9 (0.41) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL5599127 0.82 CYP2C9 (0.41) CYP2C9NPSR1GLO1ALDH1A1CYP2D6
SCHEMBL16424810 0.81 CYP2C9 (0.40) CYP2C9NPSR1GLO1ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4707276-A2 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2026-03-11 EP disclosed
EP-4499611-B1 MALT1 MODULATORS AND USES THEREOF RAREFIED BIOSCIENCES INC (US) 2026-02-18 EP disclosed
US-20250326738-A1 MALT1 Modulators and Uses Thereof RAREFIED BIOSCIENCES, INC. (US) 2025-10-23 US disclosed
EP-4499611-A1 MALT1 MODULATORS AND USES THEREOF Rarefied Biosciences, Inc. (US) 2025-02-05 EP disclosed
CN-119032083-A MALT1 modulators and uses thereof 稀有生物科学股份有限公司 2024-11-26 CN disclosed
WO-2023192506-A1 MALT1 MODULATORS AND USES THEREOF RARIFIED BIOSCIENCES, INC. (US) 2023-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326738-A1 MALT1 Modulators and Uses Thereof MALT1, SQSTM1, PPP1R10 CYP2C9 4544/4885NPSR1 4749/4885GLO1 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.